Global Fragment Based Drug Discovery Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)
Global Fragment Based Drug Discovery Market is Segmented By Component (Biophysical Techniques (NMR Spectroscopy, Differential Scanning Fluorimetry (DSF) Assay, Fluorescence Polarization, Isothermal Titration Calorimetry, X-ray Crystallography, Surface Plasmon Resonance (SPR), Bilayer Interferometry, Mass Spectrometry (MS), Capillary Electrophoresis, Weak Affinity Chromatography (WAC - HPLCUV/MS), Other assays (biochemical)), Non-biophysical Techniques), By Application (Oncology, Central Nervous System (CNS) Disorders, Infectious Diseases, Cardiovascular Diseases, Metabolic Disorders, Inflammation & Autoimmune Diseases), By End-user (Academic & Research Institutions, Pharmaceutical & Biotechnology Companies, Contract Research Organizations (CROs), Others), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD billion) for the above-mentioned segments.
Competitive overview of Global Fragment Based Drug Discovery Market
The major players operating in the Global Fragment Based Drug Discovery Market include Emerald BioStructures, Inc., Crown Bioscience, Vernalis Research, Sygnature Discovery, Shanghai ChemPartner, SARomics Biostructures, Red Glead Discovery, Domainex, CRELUX, ComInnex, Creative Biolabs, ChemAxon, 2bind, Amgen and University of California, San Francisco.
Global Fragment Based Drug Discovery Market Leaders
- Astex Pharmaceuticals
- Beactica AB
- Charles River Laboratories International, Inc.
- Evotec AG
- Alveus Pharmaceuticals Pvt. Ltd.
Global Fragment Based Drug Discovery Market - Competitive Rivalry, 2023
Global Fragment Based Drug Discovery Market
(Dominated by major players)
(Highly competitive with lots of players.)